Run the same analysis on the same data. You should get the same result. Every time.
In clinical research, that simply isn’t a best practice. It’s a regulatory expectation.
Yet, a surprising number of clinical research teams still rely on individual analysts, local computing environments and manual documentation to ensure reproducibility.
That distinction often doesn’t become apparent until the stakes are the highest: during a regulatory review, ahead of a submission deadline, or in a response to an FDA Complete Response Letter.
How reproducibility breaks down
The failure modes are more varied than most people expect. Some are obvious: teams update a dataset between runs without locking the analysis to a specific version.
Others are subtle: an R package update changes the behavior of a function that no one realized was version-sensitive. Or a Python dependency shifts quietly and the output from this quarter doesn't quite match last quarter's – and no one can immediately explain why.
In local or fragmented analytical environments, these risks multiply. Different analysts may unknowingly run different software versions in different configurations. A process that appears consistent at the individual level can yield materially different results when teams aggregate data without standardizing the computational environment.
Documentation creates another point of failure. In disconnected environments, one analyst may carefully document every step while another relies on institutional knowledge.
Neither approach gives a regulatory reviewer the complete, reproducible picture they need without significant additional effort.
The regulatory reality
Reproducibility is a regulatory obligation in clinical research. The FDA's guidance on computerized systems used in clinical investigations and the broader ICH E6(R3) Good Clinical Practice framework are explicit about data integrity, audit trails and the ability to reconstruct and validate analytical processes at any point in the research lifecycle.
When an organization can't definitively demonstrate how it arrived at a result – and prove it can reproduce that result on demand – the path to submission gets longer and more expensive. Queries lead to remediation, remediation leads to delays and delays carry costs that go well beyond the financial: they extend the time between a therapy's clinical readiness and the patients who need it.
Reproducibility by design
SAS® Clinical Acceleration approaches reproducibility differently. Rather than relying on manual processes, it builds reproducibility into the platform itself. Teams version, document and trace every analysis alongside the data, code and computational environment used to produce it. When an analyst – or a regulator – needs to revisit an analysis, they can reconstruct the complete analytical context without ambiguity.
This extends across all supported languages. Whether an analysis is written in SAS, R or Python, the reproducibility properties are the same. The audit trail captures what was done, by whom, under what conditions – regardless of how the analysis was written.
The platform's integration with electronic data capture systems, clinical data management systems, labs and CROs adds another layer of integrity. Because the same system governs the source data, it maintains a documented, unbroken lineage from source to analysis to output.
The cost of getting it wrong
I want to be direct about what reproducibility failures actually cost, because the magnitude is often softened in platform conversations.
An FDA Complete Response Letter triggered by a reproducibility issue doesn't just delay a submission. In a competitive therapeutic area, it can mean losing the first-mover advantage to a competitor who submitted cleanly. In a rare disease program, it can mean patients waiting years longer for a treatment that was clinically ready. In any program, it means reanalysis, additional documentation and months of remediation work that could have been avoided entirely.
Reproducibility isn't something organizations should have to engineer into every study. It should be a property of the environment itself. When that's true, teams spend less time recreating analyses, responding to regulatory questions and documenting work after the fact – and more time advancing therapies for the patients waiting on the other side of every submission.
